Eptinezumab
Anti-CGRP ligand monoclonal antibody
Eptinezumab
Vyepti
Eptinezumab (brand name Vyepti) is the only IV-administered anti-CGRP monoclonal antibody, FDA-approved in 2020 for migraine prevention. The IV route gives faster onset than the subcutaneous CGRP mAbs.
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Classes
Anti-CGRP ligand monoclonal antibody
Common uses
Preventive treatment of migraine in adults
Pharmacy
Starting dose
100 mg IV every 3 months; may increase to 300 mg IV every 3 months
Preparations
100 mg/mL vial for IV infusion
US FDA Max
300 mg/quarter
Pharmacology
Routes
Intravenous infusion
Onset
Effect demonstrated within 24 hours in some patients
Duration
3-month dosing interval
Half-life
~27 days
Bioavailability
100% (IV)
Pregnancy
Limited data; avoid
Legal status
Rx
Purported mechanism
Humanized IgG1 monoclonal antibody binding CGRP peptide; IV infusion enables fastest onset of any CGRP mAb